Investigational drug · Phase 3
PF-06823859
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Myositis.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "PF-06823859"
First trial start
2023
May 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-06823859", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myositis
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-06823859" as an intervention, largest first.
- A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]Pivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT05895786 · 318 participants (planned) · Start May 20, 2023 · Primary completion Jul 29, 2030
Drug: PF-06823859; Placebo · For: Myositis
Sites: Glendale, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 138 sites in all
PfizerPfizer (PFE)
NCT03181893 · 75 participants · Start Jan 23, 2018 · Primary completion May 27, 2022
Drug: PF-06823859 low; Placebo Arm and 1 more · For: Dermatomyositis
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 41 sites in all
PfizerPfizer (PFE)
NCT02766621 · 62 participants · Start May 27, 2016 · Primary completion Aug 30, 2017
Drug: PF-06823859; Placebo injection SC/IV · For: Healthy
Sites: New Haven, Connecticut
PfizerPfizer (PFE)
NCT05192200 · 24 participants · Start Dec 20, 2021 · Primary completion Nov 20, 2023
Drug: Anti-Beta Interferon (PF-06823859) · For: Dermatomyositis
Sites: Birmingham, Alabama; Scottsdale, Arizona; Beverly Hills, California · 25 sites in all
- A Study to Learn About The Study Medicine (Called PF-06823859) in Healthy Chinese ParticipantsCompleted
PfizerPfizer (PFE)
NCT05257798 · 18 participants · Start Feb 28, 2022 · Primary completion Mar 21, 2023
Drug: IFN-β inhibitor treatment · For: Healthy
Sites: Beijing, China · 2 sites in all
PfizerPfizer (PFE)
NCT05037409 · 13 participants · Start Sep 28, 2021 · Primary completion Mar 27, 2022
Drug: PF-06823859; Placebo · For: Healthy
Sites: Shinjuku-ku, Japan
PfizerPfizer (PFE)
NCT05879718 · 8 participants · Start Jul 7, 2023 · Primary completion Jun 5, 2025
Drug: Placebo; PF-06823859 · For: Lupus Erythematosus, Systemic; Lupus Erythematosus, Cutaneous
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and Safety of Dazukibart for Dermatomyositis: A Systematic Review.
Bai JQA, Lordfard S, Geng RSQ, et al. · J Cutan Med Surg 2026
- Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S, Oemar B, Johnson K, et al. · Clin Pharmacol Drug Dev 2021
Also in development for Myositis
- GlucocorticoidsPhase 37 trials
Novartis · VEXAS Syndrome, ANCA Associated Vasculitis (AAV), Anti-Glomerular Basement Membrane Disease
- CRT-402Phase 21 trial
Myeloid Therapeutics · Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.